Intravenous immunoglobulin or intralipid treatment for recurrent pregnancy loss or implantation failures women with NK cell abnormality

Intravenous immunoglobulin or intralipid treatment for recurrent pregnancy loss or implantation failures women with NK cell abnormality - IVIG or intralipid treatment for RPL or IF women with NK cell abnormality

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038952

Enrollment

100

Registered

2019-12-24

Start date

2017-10-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent pregnancy loss, implantation failure

Interventions

IVIG: every 4 weeks Intralipid: every 2 to 4 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: RPL or IF women with NK cell abnormality

Exclusion criteria

Exclusion criteria: Untreated other causes of infertility or RPL Allergy for IVIG or intralipid

Design outcomes

Primary

Measure	Time frame
For recurrent pregnancy loss women with NK cell abnormality: ongoing pregnancy rate at 22 weeks of pregnancy For implantation failure women with NK cell abnormality: pregnancy rate and ongoing pregnancy rate at 22 weeks of pregnancy	—

Countries

Japan

Contacts

Public ContactAtsushi Fukui

Hyogo College of Medicine Obstetrics and Gynecology

at-fukui@hyo-med.ac.jp0798-45-6481

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026